Fluorouracil and dose-dense chemotherapy in adjuvant treatment of patients with early-stage breast cancer

IMPACT: This trial showed that the addition of fluorouacil to EC-P did not improve survival and increased toxicity. The dose-dense regimen was associated with a significant reduction in the risk of recurrence and death compared with standard-interval chemotherapy. Unlike the CALGB B9741, the benefit was shown for hormone receptor positive and negative subgroups.

Download | Slideshow Summary

Link | Full article (PubMed)